1,031
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Outsourcing of research and development and efficiency: a DEA non-parametric analysis of the contract research organisations industry

& ORCID Icon
Article: 2153374 | Received 20 May 2022, Accepted 21 Nov 2022, Published online: 14 Dec 2022

References

  • Boljunčić, V. (2006). Sensitivity analysis of an efficient DMU in DEA model with variable returns to scale (VRS). Journal of Productivity Analysis, 25(1–2), 173–192. https://doi.org/10.1007/s11123-006-7139-5
  • Chase, D., Gierend, M., Letzel, H., & Ludwig, S. (2001). System audit of contract research organizations in Germany. International Journal of Pharmaceutical Medicine, 15(4), 191–193.
  • Daraio, C., & Simar, L. (2007). Conditional nonparametric frontier models for convex and nonconvex technologies: A unifying approach. Journal of Productivity Analysis, 28(1–2), 13–32. https://doi.org/10.1007/s11123-007-0049-3
  • DeCorte, B. L. (2020). Evolving outsourcing landscape in pharma R&D: Different collaborative models and factors to consider when choosing a contract research organization: Mini perspective. Journal of Medicinal Chemistry, 63(20), 11362–11367. https://doi.org/10.1021/acs.jmedchem.0c00176
  • Ding, B. (2018). Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. Process Safety and Environmental Protection, 119, 115–130. https://doi.org/10.1016/j.psep.2018.06.031
  • Drabu, S., Gupta, A., & Bhadauria, A. (2010). Emerging trends in contract research industry in India. Contemporary Clinical Trials, 31(5), 419–422. https://doi.org/10.1016/j.cct.2010.06.008
  • Díaz, R. F., & Sanchez-Robles, B. (2021). Efficiency in the CRO industry, 2010–2019. Available at SSRN: https://ssrn.com/abstract=3839735
  • Falavigna, G., & Ippoliti, R. (2021). Reform policy to increase the judicial efficiency in Italy: The opportunity offered by EU post-COVID funds. Journal of Policy Modeling, 43(5), 923–943. https://doi.org/10.1016/j.jpolmod.2021.06.001
  • Gascón, F., Lozano, J., Ponte, B., & de la Fuente, D. (2017). Measuring the efficiency of large pharmaceutical companies: An industry analysis. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 18(5), 587–608. https://doi.org/10.1007/s10198-016-0812-3
  • Getz, K. A., & Vogel, J. R. (2009). Successful outsourcing: Tracking global CRO usage. Applied Clinical Trials, 18(6), 42.
  • Getz, K. A., Lamberti, M. J., & Kaitin, K. I. (2014). Taking the pulse of strategic outsourcing relationships. Clinical Therapeutics, 36(10), 1349–1355. https://doi.org/10.1016/j.clinthera.2014.09.008
  • Gummerus, A., Airaksinen, M., Bengtström, M., & Juppo, A. (2016). Outsourcing of regulatory affairs tasks in pharmaceutical companies—Why and what? Journal of Pharmaceutical Innovation, 11(1), 46–52. https://doi.org/10.1007/s12247-015-9235-4
  • Hassanzadeh, F., Modarres, M., Nemati, H. R., & Amoako-Gyampah, K. (2014). A robust R&D project portfolio optimization model for pharmaceutical contract research organizations. International Journal of Production Economics, 158, 18–27. https://doi.org/10.1016/j.ijpe.2014.07.001
  • Huang, J. (2019). Contract research organizations are seeking transformation in the pharmaceutical value chain. ACS Medicinal Chemistry Letters, 10(5), 684–686. https://doi.org/10.1021/acsmedchemlett.9b00046
  • Kneip, A., Park, B. U., & Simar, L. (1998). A note on the convergence of nonparametric DEA estimators for production efficiency scores. Econometric Theory, 14(6), 783–793. https://doi.org/10.1017/S0266466698146042
  • Koch, G., Leitner, K. H., & Bornemann, M. (2000, October). Measuring and reporting intangible assets and results in a European Contract Research Organization. In Joint German-OECD Conference Benchmarking Industry-Science Relationships, pp 16–17.
  • Korhonen, P. J., & Luptacik, M. (2004). Eco-efficiency analysis of power plants: An extension of data envelopment analysis. European Journal of Operational Research, 154(2), 437–446. https://doi.org/10.1016/S0377-2217(03)00180-2
  • Krishnamoorthy, K., & Yu, J. (2004). Modified Nel and Van der Merwe test for the multivariate Behrens–Fisher problem. Statistics & Probability Letters, 66(2), 161–169. https://doi.org/10.1016/j.spl.2003.10.012
  • Kümmerer, K. (2010). Pharmaceuticals in the environment. Annual Review of Environment and Resources, 35(1), 57–75. https://doi.org/10.1146/annurev-environ-052809-161223
  • Lamberti, M. J., Wilkinson, M., Harper, B., Morgan, C., & Getz, K. (2018). Assessing study start-up practices, performance, and perceptions among sponsors and contract research organizations. Therapeutic Innovation & Regulatory Science, 52(5), 572–578. https://doi.org/10.1177/2168479017751403
  • Lee, T. Y. (1998). Contract research organizations. Drug Information Journal, 32(1_suppl), 1259S–1263S. https://doi.org/10.1177/00928615980320S117
  • Lowman, M., Trott, P., Hoecht, A., & Sellam, Z. (2012). Innovation risks of outsourcing in pharmaceutical new product development. Technovation, 32(2), 99–109. https://doi.org/10.1016/j.technovation.2011.11.004
  • Masri, M. D., Ramirez, B., Popescu, C., & Reggie, E. M. (2012). Contract research organizations: An industry analysis. International Journal of Pharmaceutical and Healthcare Marketing, 6(4), 336–350. https://doi.org/10.1108/17506121211283226
  • Mirowski, P., & Van Horn, R. (2005). The contract research organization and the commercialization of scientific research. Social Studies of Science, 35(4), 503–548. https://doi.org/10.1177/0306312705052103
  • Piachaud, B. S. (2002). Outsourcing in the pharmaceutical manufacturing process: An examination of the CRO experience. Technovation, 22(2), 81–90. https://doi.org/10.1016/S0166-4972(01)00081-5
  • Piachaud, B. (2005). Outsourcing technology. Research-Technology Management, 48(3), 40–46. https://doi.org/10.1080/08956308.2005.11657314
  • OECD. (2022). https://stats.oecd.org/Index.aspx?DataSetCode=G20_PRICES.
  • Rahman, M., Rodríguez-Serrano, M. Á., & Lambkin, M. (2020). Advertising efficiency and profitability: Evidence from the pharmaceutical industry. Industrial Marketing Management, 89, 619–629. https://doi.org/10.1016/j.indmarman.2019.02.001
  • Sanchez-Robles, B., Herrador-Alcaide, T., & Hernández-Solís, M. (2022). Efficiency of European oil companies: An empirical analysis. Energy Efficiency, 15(8), 63. https://doi.org/10.1007/s12053-022-10069-2
  • Sariola, S., Ravindran, D., Kumar, A., & Jeffery, R. (2015). Big-pharmaceuticalisation: Clinical trials and contract research organisations in India. Social Science & Medicine (1982), 131, 239–246. https://doi.org/10.1016/j.socscimed.2014.11.052
  • Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191–200. https://doi.org/10.1038/nrd3681
  • Simar, L., & Wilson, P. W. (1998). Sensitivity analysis of efficiency scores: How to bootstrap in nonparametric frontier models. Management Science, 44(1), 49–61. https://doi.org/10.1287/mnsc.44.1.49
  • Simar, L., & Wilson, P. W. (2000). A general methodology for bootstrapping in non-parametric frontier models. Journal of Applied Statistics, 27(6), 779–802. https://doi.org/10.1080/02664760050081951
  • Simar, L., & Wilson, P. W. (2007). Estimation and inference in two-stage, semi-parametric models of production processes. Journal of Econometrics, 136(1), 31–64. https://doi.org/10.1016/j.jeconom.2005.07.009
  • Shi, Y. Z., Hu, H., & Wang, C. (2014). Contract Research Organizations (CROs) in China: Integrating Chinese research and development capabilities for global drug innovation. Globalization and Health, 10(1), 1–6. https://doi.org/10.1186/s12992-014-0078-4
  • Steadman, V. A. (2018). Drug discovery: Collaborations between contract research organizations and the pharmaceutical industry. ACS Medicinal Chemistry Letters, 9(7), 581–583. https://doi.org/10.1021/acsmedchemlett.8b00236
  • Sueyoshi, T., & Goto, M. (2012). Returns to scale and damages to scale under natural and managerial disposability: Strategy, efficiency and competitiveness of petroleum firms. Energy Economics, 34(3), 645–662. https://doi.org/10.1016/j.eneco.2011.07.003
  • Van Dijk, B. (2022). Orbis database. Bureau van Dijk Electronic Publishing. https://www.bvdinfo.com/en-gb/.
  • Wilson, P. W. (2018). Dimension reduction in nonparametric models of production. European Journal of Operational Research, 267(1), 349–367. https://doi.org/10.1016/j.ejor.2017.11.020
  • Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA, 323(9), 844–853. https://doi.org/10.1001/jama.2020.1166
  • Wu, Q., & He, Q. (2020). DIY Laboratories and business innovation ecosystems: The case of pharmaceutical industry. Technological Forecasting and Social Change, 161, 120336.
  • Xia, C., & Gautam, A. (2015). Biopharma CRO industry in China: Landscape and opportunities. Drug Discovery Today, 20(7), 794–798. https://doi.org/10.1016/j.drudis.2015.02.007